Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (DE:1JK)
FRANKFURT:1JK
RESEARCH TOOLSreports
Apellis Pharmaceuticals (1JK) Stock Price & Analysis
0 Followers
1JK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€19.00 - €87.50
Previous Close€43.81
Volume0.00
Average Volume (3M)245.00
Market Cap
€5.31B
Enterprise Value€5.09B
Total Cash (Recent Filing)$351.20M
Total Debt (Recent Filing)$110.93M
Price to Earnings (P/E)N/A
Beta0.33
Next Earnings
May 07, 2024EPS Estimate
-€0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding120,581,749
10 Day Avg. Volume7
30 Day Avg. Volume245
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)29.42
Price to Sales (P/S)36.09
Price to Cash Flow (P/CF)-14.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.01
Enterprise Value/Gross Profit13.05
Enterprise Value/Ebitda-9.85
Forecast
1Y Price Target
€74.69Price Target Upside71.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Safety And EfficacyThe rate of retinal vasculitis cases associated with Syfovre has been declining, suggesting an improving safety trend.
Market ExpansionIncreased use of both Syfovre and Izervay primarily comes from doctors practicing in community settings, suggesting market expansion in those areas.
Regulatory CatalystApellis expects a new CHMP opinion by July 2024, indicating a potential near-term catalyst for the stock.
Bears Say
Drug Safety ConcernsFor APLS' Syfovre, there were 73 additional serious adverse events reported, including 10 additional cases of retinal vasculitis and 2 deaths.
Market CompetitionSurvey results suggest a loss of Syfovre's market share leadership within just one year, highlighting competitive pressures.
Regulatory ChallengesApellis Pharmaceuticals is facing a re-review of pegcetacoplan for GA due to potential conflicts of interest in the original expert group, which could negatively impact approval prospects.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
6.01% Other Institutional Investors
93.99% Public Companies and
Individual Investors
1JK FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was €19.00 and its highest was €87.50 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2024 which is today.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Feb 27, 2024. The company reported -€0.678 earnings per share for the quarter, beating the consensus estimate of -€0.679 by <€0.001.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -€0.42.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Currently, no data Available
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -€0.678 in its last earnings report, beating expectations of -€0.679. Following the earnings report the stock price went up 4.8%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Driehaus Capital Management LLC. It holds Apellis Pharmaceuticals Inc’s shares valued at 29M.
---
Apellis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€74.69 (71.83% Upside)
€74.69 (71.83% Upside)
Blogger Sentiment
Bullish
DE:1JK Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.17%
12-Months-Change
Fundamentals
Return on Equity
-290.14%
Trailing 12-Months
Asset Growth
3.75%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
1JK Company Deck
---
1JK Earnings Call
Q4 2024
0:00 / 0:00
---
1JK Stock 12 Months Forecast
Average Price Target
€74.69
▲(71.83% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Ultragenyx Pharmaceutical
―
Karyopharm Therapeutics
―
Best Analysts Covering 1JK
1 Year
1 Year Success Rate
15/23 ratings generated profit
1 Year Average Return
+18.19%
assigned a buy rating 5 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +18.19% per trade.
---